A Cross-Sectional Patient-Reported Study To Assess The Patient Preference Of Treatment Administration Setting, Impact On Health-Related Quality Of Life, Work Productivity, Wider Societal Costs And Healthcare Utilisation For Patients With Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Prescribed Somatuline® Autogel® In A Homecare Setting and Hospital Setting.
Latest Information Update: 08 Jul 2022
At a glance
- Drugs Lanreotide (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions
- Acronyms PREF-NET
- Sponsors Ipsen
- 05 Jul 2022 Status changed from recruiting to completed.
- 21 Apr 2022 Planned number of patients changed from 100 to 90.
- 21 Apr 2022 Planned End Date changed from 31 Mar 2022 to 31 May 2022.